We collaborate with reputed organisations with the vision to bring revolution in the healthcare sector. Their firm belief in our philosophy has helped us together create a valuable impact in society.
In 2006, Cadila Pharma entered into a joint venture with Apollo Hospitals Group to manage Apollo Hospitals, Ahmedabad. Over the last decade, it has been recognised as a centre of excellence and has emerged as a trusted destination for patients in the region.
In 2008, Cadila Pharma formed a JV with StemCyte Inc. USA, an organisation dedicated to the collection, processing, testing and storage of both private and public umbilical cord blood units and their therapeutic applications.
In 2015, Cadila Pharma entered into a strategic agreement with Sweden-based EQL Pharma for product development, manufacturing and marketing in the Nordic region.
In 2017, Cadila Pharma entered into a collaboration with Aplagon Oy, Finland, for the development and commercialisation of a heparin proteoglycan mimetic for use in certain vascular surgeries.
In 2019, Cadila Pharma partnered with Serca Pharmaceuticals across nonclinical development and Phase 1 and Phase 2 clinical trials, with a clear focus on establishing Proof of Concept in Phase 2, followed by global development and commercialisation, supported by a balanced approach of organic growth and strategic collaborations with leading industry players.
Our Story
Businesses
Therapies
Corporate Identification No : U24231GJ1991PLC015132
©2026 Cadila Pharmaceuticals. All rights reserved
